Adding targeted tumor treatment to standard therapy for limited metastatic colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a precise, targeted treatment to destroy remaining cancer spots (called total ablative therapy) after initial chemotherapy can improve outcomes for people with limited metastatic colorectal cancer. It aims to see if this extra treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have a confirmed diagnosis of colorectal cancer that has spread (metastatic) to other parts of the body
- Must have received at least 12 weeks (but not more than 52 weeks) of first-line chemotherapy for the metastatic disease and it must not be growing during this treatment
- Have no more than 4 visible areas of cancer spread (besides the primary tumor), and these areas must be removable or treatable with surgery or focused radiation
- Must not have cancer only in the liver—there must be at least one other site of spread besides the liver, or if you started with liver plus other sites, you can have liver-only after initial therapy
- Primary tumor must be removed, or be removable by surgery, or (for rectal cancer) have had a complete response with no regrowth
- No known MSI-high (a genetic marker) or BRAF V600E mutation, and no cancer spread to the peritoneum (lining of the abdomen) or omentum
- Be generally healthy enough (able to care for yourself, ECOG 0-2) and have adequate organ function (kidney, liver, blood counts)
- Not be pregnant or nursing, and agree to use birth control if of childbearing potential
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of ultra-precise radiation therapy, immunotherapy, chemotherapy, and targeted therapy for people with metastatic colorectal cancer that has a normal DNA mismatch repair system. The goal is to see if this personalized approach can better control the cancer and improve outcomes.
This study tests a combination of precisely targeted radiation (SBRT) with two drugs: fruquintinib (a pill that blocks blood supply to tumors) and antibodies that boost your immune system to fight cancer (PD-1 and CTLA-4 inhibitors). It is for people with advanced colorectal cancer who have already tried two standard chemotherapy treatments.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a combination of short-course radiation, chemotherapy, targeted therapy (bevacizumab), and an immunotherapy drug (PD-1 inhibitor) for people with advanced colorectal cancer that has spread and is not curable with surgery. It aims to see if this approach can help shrink tumors and improve outcomes.
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
This Phase 2 study tests the best way to choose and then follow treatment when colorectal cancer has spread only to a small number of spots. You may be eligible if your doctors can remove or precisely treat the spots and there’s no sign of additional spread on scans.
Hear when a new Metastatic Colorectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.